Pfizer and Moderna said on Tuesday they will be ready with COVID-19 vaccines designed to combat the BA.1 Omicron variant that was dominant last winter earlier than those designed to target currently dominant versions of Omicron.
Pfizer studied two potential vaccines: a monovalent shot that targets only Omicron, and a bivalent combination booster that adds Omicron to the original vaccine.